CD274 and neoplasm: At the 3-year follow-up of CheckMate 227, nivolumab plus ipilimumab provided durable long-term efficacy benefits versus chemotherapy, regardless of tumor PD-L1 expression, in the Asian subpopulation, including Japanese patients with metastatic NSCLC [21].